脐血来源干细胞治疗早产儿疾病临床研究进展与挑战  

Progress and challenges in clinical research of umbilical cord blood transplantation for the treatment of premature infant diseases

作　　者：李芳[1] 王利[1] LI Fang;WANG Li(Department of Pediatrics,Women and Children’s Hospital of Chongqing Medical University,Chongqing 401120,China)

机构地区：[1]重庆医科大学附属妇女儿童医院儿科,重庆401120

出　　处：《临床儿科杂志》2023年第10期646-653,共8页Journal of Clinical Pediatrics

基　　金：国家重点研发计划(No.2022YFC2704801);重庆市自然科学基金(No.cstc2021jcyj-msxmX0257);重庆市科卫联合重点项目(No.2023ZDXM024);重庆市科卫联合青年项目(No.2023QNXM037)。

摘　　要：尽管新生儿疾病治疗技术取得了巨大进步,早产儿疾病如支气管肺发育不良、围生期脑损伤和坏死性小肠结肠炎等疾病仍是我国新生儿死亡的重要原因,也严重影响存活早产儿远期生存质量。探寻更有效的防治手段,是新生儿领域关注的焦点。过去20年来,干细胞治疗特别是脐血来源的干细胞作为多种早产疾病的新型治疗策略,取得了鼓舞人心的临床前研究和临床研究结果,现就脐血来源干细胞治疗在早产儿疾病治疗中的临床研究与应用进展作一介绍,分别就脐血来源干细胞治疗的研究现状、存在问题及挑战进行探讨。Despite great progress in the treatment of neonatal diseases,complications of preterm infants such as bronchopulmonary dysplasia,perinatal brain injury and necrotizing enterocolitis are still leading causes of neonatal mortality and long term morbidity.Exploring more effective therapies for the prevention or treatment for the complications of preterm infants are the concerns in neonatology.Stem cell therapy especially umbilical cord blood transplantation,have been explored as a new therapeutic option in premature infant diseases,with very promising preclinical and clinical results over the past 20years.This article outlined the clinical progress,prospects and challenges of stem cells derived from umbilical cord blood in preterm diseases.

关 键 词：细胞治疗 脐血来源干细胞 早产儿 临床研究 

分 类 号：R722.6[医药卫生—儿科]